Low Primary and Secondary HIV Drug-Resistance after 12 Months of Antiretroviral Therapy in Human Immune-Deficiency Virus Type 1 (HIV-1)-Infected Individuals from Kigali, Rwanda
Low Primary and Secondary HIV Drug-Resistance after 12 Months of Antiretroviral Therapy in Human Immune-Deficiency Virus Type 1 (HIV-1)-Infected Individuals from Kigali, Rwanda
复制标题
DOI：
10.1371/journal.pone.0064345
复制
发表时间：
2013-08-12
期刊：
影响因子：
3.7
通讯作者：
Ondoa, Pascale
中科院分区：
文献类型：
--
作者：
Rusine, John;Asiimwe-Kateera, Brenda;Ondoa, Pascale
在卢旺达接受抗逆转录病毒疗法的艾滋病毒患者的治疗结果几乎没有记录。在一项对基加利开始一线治疗的抗逆转录病毒初治HIV患者的前瞻性队列研究中，确定了第12个月时的HIV病毒载量（VL）和HIV耐药（HIVDR）结局。通过临床和定期CD4计数和靶向HIV病毒载量（VL）监测治疗反应，以确认药物失败。对基线和第12个月样本进行回顾性VL测量和HIV DR基因分型。完成第12个月随访访视的158名参与者在第12个月时获得了VL数据。其中大多数（88%）为病毒学抑制（VL
Treatment outcomes of HIV patients receiving antiretroviral therapy (ART) in Rwanda are scarcely documented. HIV viral load (VL) and HIV drug-resistance (HIVDR) outcomes at month 12 were determined in a prospective cohort study of antiretroviral-naive HIV patients initiating first-line therapy in Kigali. Treatment response was monitored clinically and by regular CD4 counts and targeted HIV viral load (VL) to confirm drug failure. VL measurements and HIVDR genotyping were performed retrospectively on baseline and month 12 samples. One hundred and fifty-eight participants who completed their month 12 follow-up visit had VL data available at month 12. Most of them (88%) were virologically suppressed (VL